Table 3.
Interactions of other azoles and ED against five FLC resistant isolates by microdilution assay.
| Clinical isolates | MIC80 (μg/ml) alonea | MIC80 (μg/ml) in combination | FICIb | ||||
|---|---|---|---|---|---|---|---|
| KCZ | ICZ | ED | KCZ/ED | ICZ/ED | KCZ/ED | ICZ/ED | |
| 24D | 1 | >8 | >128 | 0.03125/2 | 2/0.5 | 0.047 | 0.253 |
| 28I | 16 | >8 | >128 | 0.125/8 | 2/8 | 0.070 | 0.312 |
| CA102 | 4 | >8 | >128 | 0.25/4 | 0.5/8 | 0.093 | 0.128 |
| CA901 | >16 | >8 | >128 | 0.0625/4 | 0.5/8 | 0.035 | 0.128 |
| CA112869 | 16 | >8 | >128 | 0.0625/8 | 1/8 | 0.066 | 0.187 |
a
ED, eucalyptal D; KCZ, ketoconazole; ICZ, itraconazole.
b
Synergism and antagonism were defined by FICI of ≤ 0.5 and >4, respectively. An FICI index result of >0.5 but ≤ 4 was considered indifferent.